- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- ANET
- Stock Information
- Founded
- GILD 1987
- ANET 2004
- Country
- GILD United States
- ANET United States
- Employees
- GILD N/A
- ANET N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- ANET Computer Communications Equipment
- Sector
- GILD Health Care
- ANET Telecommunications
- Exchange
- GILD Nasdaq
- ANET Nasdaq
- Market Cap
- GILD 138.7B
- ANET 115.5B
- IPO Year
- GILD 1992
- ANET 2014
- Fundamental
- Price
- GILD $109.64
- ANET $108.58
- Analyst Decision
- GILD Buy
- ANET Strong Buy
- Analyst Count
- GILD 24
- ANET 16
- Target Price
- GILD $110.95
- ANET $110.12
- AVG Volume (30 Days)
- GILD 8.2M
- ANET 10.4M
- Earning Date
- GILD 08-07-2025
- ANET 08-05-2025
- Dividend Yield
- GILD 2.76%
- ANET N/A
- EPS Growth
- GILD 1118.07
- ANET 31.30
- EPS
- GILD 4.73
- ANET 2.37
- Revenue
- GILD $28,735,000,000.00
- ANET $7,436,546,000.00
- Revenue This Year
- GILD $1.69
- ANET $22.03
- Revenue Next Year
- GILD $3.67
- ANET $17.31
- P/E Ratio
- GILD $23.18
- ANET $45.81
- Revenue Growth
- GILD 4.68
- ANET 22.31
- 52 Week Low
- GILD $68.14
- ANET $59.43
- 52 Week High
- GILD $119.96
- ANET $133.58
- Technical
- Relative Strength Index (RSI)
- GILD 49.22
- ANET 67.11
- Support Level
- GILD $110.61
- ANET $102.68
- Resistance Level
- GILD $114.87
- ANET $107.32
- Average True Range (ATR)
- GILD 2.45
- ANET 3.52
- MACD
- GILD 0.11
- ANET 0.89
- Stochastic Oscillator
- GILD 49.76
- ANET 96.37
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.